Premium Essay

Merck's Case

In: Philosophy and Psychology

Submitted By abicurri
Words 926
Pages 4
Name: Anila B.
Merck is a very large pharmaceutical company. One of the scientists at Merck realized that Merck’s new drug for de-worming animals from parasites could also help fighting against river blindness, which is a disease that has hit places of most poverty. River blindness is a skin disease, which is transmitted by the bite of blackflies. This parasite can migrate into the eye and cause blindness. Unfortunately those who get the disease do not have the money to pay for this drug. The countries will not be able to pay for it either. So now, the ethical dilemma is whether Merck should invest in research and risk losing money, or go for profit instead. Merck believed that medicine is for the people, not for the profits. This statements, is one of the many reasons why Merck had a responsibility to develop the drug. Eliminating human suffering and curing human disease is one of the main goals for Merck. They are committed to the highest standards of ethics and integrity. Merck wants to preserve and improve human life and its quality. Coming from this it is really important to consider the ethical decision making questions. Are there other alternatives? Who will be affected? Who will benefit and who will be harmed? Let’s start with saying that yes, there is an alternative. If Merck is afraid of losing money, it should start cooperating with global donators, UNICEF, non-governmental development organizations, international foundations, as well as local communities. People from rich countries will help and donate to cure the disease. Merck does not have to put all of its money into this drug and will still be able to live up to its ethical standards and promises. In the long run he may gain profit as well.
Those who will be affected the most if this plan does not work out, will be the people who have the disease and those who are in risk of getting it. They…...

Similar Documents

Premium Essay

Merck Case Question

...Questions for the Merck Case Create a decision tree for Merck. The 2 leftmost branches would identify the alternatives related to licensing Davarink (specifically license versus not to license). Next, if Merck decides to pursue license, they go into phase I which results in a success, or failure. Phase I success is followed by phase II where Merck has the opportunity to develop the drug to treat depression alone, weight loss alone, or both, or contemplate phase II failure. Finally phase II success for different options leads to phase III, and there are success or failure related outcomes for each of the alternatives in phase II (i.e. developing the drug to treat depression, weight loss, or both). HINTS: Within each phase, remember that the probabilities of various outcomes (including failure, which is not always mentioned as an option) should add up to 100%. In each phase, the stated cost already includes fees paid to LAB. For example, cost of Phase I is $30 million (this number includes $5 million paid to LAB). A careful read of the case is critical to get the tree, various probabilities and the cash flows right. Please be sure to include your decision tree along with your answer to the questions below. 1) What is the expected value in launching Davarink as an antidepressant only? 2) What is the expected value in launching Davarink to treat only weight loss? 3) What is the expected value in launching Davarink for possibility of separate...

Words: 423 - Pages: 2

Free Essay

Case Study Merck Acquisition

...Case FIN561: Mergers and Acquisitions You decide: Merck Acquition of Medco Vikash Sharma In July 1993, Merck & Co., the largest pharmaceutical company in the world at that time, acquired Medco Containment Services for $6.6 billion. Medco was the largest prescription benefits management company. With the drug industry experiencing the effects of managed care, pharmaceutical companies had to adapt to new means of distribution. Merck realized that the decisions of what treatments and what drugs should be used in patients’ care were increasingly being influenced by the managed care environment rather than by physicians. In the world of managed care, it was no longer sufficient to market just to physicians. The successful pharmaceutical companies of the future would be companies that were able to adapt to the changed distribution system. This was a very strategic move my Merck and this vertical integration was a move that all its competitors were also targeting. In 1994 SmithKline acquired DPS for $2.2B and later that year Eli Lily acquired PCS for $4.1B. In order to understand why Merck acquired Medco, which was a pharmacy benefits management (PBM) company, we need to look at the role of this so-called PBM’s. These PBM’s have several functions * Process Pharmacy claims i.e. check for eligibility when an order is placed at the retail store, check for copayment etc * Set up Pharmacy benefit, which is to apply PBM codes to what drugs are covered under a......

Words: 973 - Pages: 4

Free Essay

Pepcid Ac Case

...prescription product with Pepcid AC, and 28%-34% would use it as a substitute for nonprescription antacids. Therefore, the OTC Pepcid AC would cannibalize both prescription sales of Merck’s Pepcid and the OTC sales of Mylanta antacid. Surprisingly, BASES II estimated that, in the first-year predication of the market, sales of Pepcid AC drawing from Mylanta only accounts for 11% of Pepcid AC’s dollar volume, and Pepcid AC drawing from prescription Pepcid only accounts for 8% (see Appendix A Figure 1). The effect of cannibalization is not significant, so the prescription Pepcid and Mylanta antacid still can keep their decent position in the market. However, as Pepcid AC has better performance in long-lasting relief and convenience than antacid in the OTC market, Pepcid AC can be expected to cannibalize JJM’s Mylanta antacid rapidly in the next a few years. c) What are the relative merits of positioning Pepcid as a “treatment” as opposed to“prevention” for heartburn/indigestion? How is this viewed by the FDA, the consumer and JJM? How important is positioning in this market? (Combined the answers of the first two questions) Firstly, FDA has serious consideration about prevention studies. FDA mostly considers education as the means to prevention rather than medication, and does not have precedent case for prevention claims. From the perspective of medication, over-medication in pursuit of prevention might mask serious medical problems. To claim “treatment” only is likely......

Words: 1071 - Pages: 5

Free Essay

Dupont Case

... As per our recommendation DuPont should divest in Conoco in a phased manner so that company can be free of non performing unit. Between 1940 and 1980, DuPont developed and marketed technologies such as Dacron, Mylar, Lycra, Kevlar, Tyvek, and Nomex. The company also expanded its pharmaceuticals and medical products business. The company acquired Conoco, an energy supplier, in 1981. In 1991, DuPont's pharmaceutical business entered into a joint venture (JV) with Merck, to focus on non-US markets. During the 1990s, the company acquired Protein Technologies International, a producer of soy protein products and Imperial Chemical's polyester-resins, a company with intermediates and polyester-films operations. In 1998, the company bought Merck's share of the pharmaceutical JV and renamed the company, DuPont Pharmaceuticals. Later that year, DuPont started selling its interests in Conoco which was completed in 1999. Conoco facility can be classified as cost center. It is one of the main cost centers of the company and hence the most resources are hogged up at this center. One needs to identify resources properly at this center so that we can classify it properly and manage it. Today it is undoubtedly that each organization, aiming at success of its business, tries to put the right people with the right skills and attributes in the appropriate positions. Executives and human resources managers are well aware that wrong decision in employees’ appointment can cause the loss of......

Words: 2240 - Pages: 9

Free Essay

Vioxx Case Analysis

...The various stakeholders that would be affected in the Merck Vioxx case would include investors or shareholders, employees, customers, suppliers, and distributors. Investors and employees would be considered the internal stakeholders while customers, suppliers, and distributors would be considered external stakeholders. The investors or shareholders are very important to Merck's success because they supply the funds for research and development through their investment in the company's stock. Without them, there really is no company. If the firm struggles, the investors are likely to lose money as well so they closely follow every decision Merck makes. Certain shareholders have the power to influence company decisions and help appoint members of power within the organization. A good example of investors with these powers would be the board of directors. The general employees within Merck effect the overall success of the firm through the decisions they make while on the job. Additionally, they are also affected by top management decisions that they can't control. If the CEO makes a poor choice that costs the company money, their jobs are at risk. The customers are very important because they are the ones buying the drug. In this case, customers are even more important because they are physically being affected by the product they are purchasing. The product needs to fill the customer's needs without harming them through adverse side effects. The customers......

Words: 633 - Pages: 3

Premium Essay

Merck Case Study

...Case Study: Merck Acquisition of Medco Professor Daniel Weiss FI561 January 23, 2011 DeVry University Case Study: Merck Acquisition of Medco Abstract The purpose of this case study is to determine whether it would be beneficial to merge Merck Corporation with Medco Containment Services Incorporated. The merger and acquisition between the world’s largest drug manufacturer and the largest prescription benefits management company (PBM) and marketer of mail order medicines in the United States would result in a successful campaign to take over the drug industry if handled appropriately. As Chairman and CEO of Merck Corporation, I have to consider all sides of the arguments, financially, marketing and cultural wise and come to a conclusion as to whether this merger would be a good idea for the company. Like any other investment and merger, there are risks, and I have to decide what would be best in the interest of this company. The details as to whether the decision to acquire or not acquire Medco will be described in this paper. Along with data that helps make that final decision. There are a few things one must take into account before making a decision. You have to look at the long term run, whether or not the merger and acquisition will be successful. You also have to take synergy into account; it is the most important reason why there are a lot of mergers and acquisitions. Synergy would be when two companies join forces to create additional value and cut......

Words: 2468 - Pages: 10

Free Essay

Case Study

...Merck, the FDA, and the Vioxx Recall In 1999 the Food and Drug Administration (FDA) had approved Vioxx, what would become Merck’s “blockbuster” drug. Although the FDA had approved the drug there was uncertainty of the safety of drug. Vioxx was approved to treat a variety of conditions, such as osteoarthritis and acute pain, but there was also a chance that it would increase cardiovascular problems. What I found most interesting about this case was the changes in how drugs are brought to consumers, from how they are approved to how they are informed of the drug. Strengths Merck was heading in the right direction with its drug Vioxx. They wanted the drug to be a “blockbuster”, used for multiple symptoms and everyday use. Merck used direct-to-consumer advertising to fuel sales of Vioxx. Vioxx seemed to benefit stakeholders on both ends of the spectrum, until it was found to cause cardiovascular problems. Merck did continue to research the effects of its drug and eventually voluntarily withdrew Vioxx. This is a strength in that they made the right ethical decision to withdraw the drug, even though it did take almost 5 years. Weaknesses Merck’s weakness would be that it did not research its drug thoroughly enough for possible problems before seeking approval from the FDA. The FDA etimates that 139,000 people in the United States had had a heart attack or stroke as a result of taking VIoxx. This could have been prevented if Merck had properly researched the drug or......

Words: 548 - Pages: 3

Premium Essay

Case

...In August 2000, following a successful arbitration against Andersen Worldwide and Arthur Andersen, Andersen Consulting was granted its independence. Now the firm faced a new challenge. As part of the ruling granting its independence, the license to use the Andersen Consulting name was to expire December 31, 2000. After spending an estimated $7 billion2 building the Andersen Consulting brand over a decade, the company now had to find, implement and introduce to the world a new name in a matter of months. Never before had a rebranding of such scope been implemented over so short a timeframe. Moreover, this rebranding also coincided with a new positioning that reflected the organization’s further growth and broadened set of capabilities. The case study that follows tells the evolution of Andersen Consulting to the newly rebranded and repositioned Accenture. COMPANY HISTORY In 1913, at the age of 28, Northwestern University economics professor Arthur Andersen founded the accounting firm Arthur Andersen & Co. Arthur Andersen envisioned an accounting firm that offered more than the standard certifications of corporate balance sheets. In his mind, a “thoroughly trained accountant [possessed] a sound understanding of the principles of economics, of finance and of organization.”3 Arthur Andersen & Co. created an early version of the consulting unit when it formed the Administrative Accounting group in 1942. The Administrative Accounting practice was charged with developing accounting......

Words: 13556 - Pages: 55

Free Essay

Meck Case Study

...It is often common to see start-ups and small biotechnology companies sell their technologies to bigger companies. The bigger companies purchase these technologies with hopes of making huge profits while the biotech companies sell in other to get finances to proceed with other business ventures or to stay in business. In order for both parties to benefit, major decisions have to be made on the method of valuation. The method used has to be objective and valid. This case study is about LAB and its decision to license off Davanrik to Merck. This analysis is about how Merck has been able to generate substantial returns given the costly and lengthy time to develop drugs and the potential outcome for Davanrik should LAB licenses off to Merck, Also, the analysis will determine if Merck should license the drug and for how much, and to determine how much LAB would receive given a 5% royalty fee on any cash flow. Lastly, the paper will analyze the change in launching Davanrik for weight loss if the cost was $225 million instead of $100 million. Merck is a giant pharmaceutical company that concentrates on research and development of new drugs. It performs several research and develops medical products for humans and animals. Merck owns lots of blockbuster medical supplies and drugs. In 1999, it earned $5.9 billion in sales, an increase of about 20% from 1998 (Ruback, 2003). Merck makes huge profits from its patented drugs like Vasotec, Prinivil and Pepcid. Merck is able to achieve......

Words: 963 - Pages: 4

Premium Essay

Case

...1. How has Merck been able to achieve substantial returns to capital given the large costs and lengthy time to develop drugs? Merck had a 14% increase in sales between 1997 and 1998 and 22% increase in sales from 1998 – 1999, and a 13% annual increase in earnings over the same period. Merck’s business strategy consists of two parts: (1) developing and marketing new drugs through internal research, and (2) developing partnerships with smaller biotechnology companies. Since 1995, Merck had launched 15 new products that earned $5.9 billion on sales of $32.7 billion. Furthermore, Merck may agree to license new drugs from other firms and with its larger capital and greater assets, can assume the risk of submitting the drug through various regulatory approval phases. If the drug becomes profitable, Merck can earn significant cash flows while paying a royalty to the licensor. However, most important is the option that Merck has in deciding when to abandon or continue on this project (deferability or optionality). If Merck reaches a point when its expected NPV is negative, it can simply abandon the project. As a licensee, Merck can allow smaller biotechnology firms to focus on research and development. These smaller firms often have smaller budgets and are not financially or personnel equipped to handle the costly and long FDA approval process, and the subsequent marketing, distribution, and sales of new drugs. This task is better suited for a larger company, such as......

Words: 658 - Pages: 3

Free Essay

Merck Case

...Conflict and Change Harvard Case Study Professor: Robert Lazer PhD Team: Zerrin Hejazi, Mark Klabonski, Elizabeth Lamb, Hari Thenneti Pandurangamoorthi, & Hareshkumar Surani The History of Merck U.S. sales office opened in and George Merck, Heinrich’s grandson, was appointed head of the U.S. branch Friedrich Jacob Merck opened Merck in Germany 1668 1827 Heinrich E Merck transformed the business and Merck began manufacturing 1887 Merck merged with Philadelphia pharmacy Sharp & Dohme 1891 The renamed company Merck & Co. opens for business 1953 2009 Merck merged with ScheringPlough Corporation and Organon BioSciences Pharmaceutical Industry • The average drug development time is over fifteen years with an average R&D expenditure of $800 million. • The FDA requires three phases of testing to assess safety and effectiveness. o Test results dictate what is displayed on the drug’s label and how the doctor will prescribe it. • Follow-up studies (Phase 5) can be performed to assess the drug after market release (Phase 4) and amend the drug label for improved sales. Pharmaceutical Success • 1981 to 2001, Merck experienced an upward trend on several industry metrics. • Their Return on Sales (ROS) for their Human Pharma line peaked at just over 40% in 2001 with an average of 24% . • The early 1990’s exhibited a downward trend just prior to Gilmartin assuming the role of CEO. Pharmaceutical......

Words: 3826 - Pages: 16

Premium Essay

Merck's Business Environment

...Merck’s Business Environment MNGT/521 University of Phoenix November 7, 2011 Kevin Wilhelmsen Merck’s Business Environment There are many factors a business, such as Merck, must have in order to be successful, for example strong financial statements, leading technology, and globalization. With the help of income statements, balance sheets, and cash flow statements, a financial analysis can be applied in a wide variety of situations to give business managers the information they need to make critical decisions (Financial Analysis, 2010). They also provide information in regards to the financial health of a company. Pharmaceutical companies are using technology to conduct clinical trials, which has proven to be beneficial to research, development, and the introduction of new products. Globalization is also important for Merck when it comes to product distribution. Outsourcing was been adopted by Merck in order to produce equal quality vaccines and medications at a cheaper cost. Review of Finances Analyzing a company’s income statement, balance sheet, and cash flow is a prime way in determining their success. A comparison can be made between the competition in the industry and a leader can be established. An analysis can also show which company is spending more on research and development and in turn, producing better products. After review of the income statements, Merck’s worldwide sales were $12......

Words: 2950 - Pages: 12

Premium Essay

Accounting Case

...1. How many of its common shares is Merck authorized to issue as of 12/31/11? Merck authorized 6,500,000,000 shares. 2. How many of its common shares has Merck actually issued as of 12/31/11? Merck issued 3,576,948,356 shares. 3. How many of its common shares does Merck hold in its treasury as of 12/31/11? 536,109,713 shares 4. How many of Merck’s common shares are outstanding as of 12/31/11? 3,040,838,643 shares 5. How many of its shares did it repurchase during 2011? 58,000,000 shares 6. How much per share, on average, did Merck pay to buy back its stock in 2011? Price per share = 1,921,000,000/58,000,000= $33.12/share 7. Why doesn’t Merck treat its Treasury Stock as an asset on its balance sheet? Briefly explain. Merck's Treasury Stock is not an asset account. It is Merck’s own stock. Merck buys it back to reduce its outstanding stock available on the market. Merck can not legally invest in its own stock and can not make profit from its own stock. It is considered as a contra equity account that reduces shareholder equity on the balance sheet. 8. How much did Merck declare during 2011 in dividends to its common shareholders? $4,818,000,000 9. How much did Merck pay during 2011 in dividends to its common shareholders? $4,691,000,000 10. Record the summary journal entry that Merck would make for its common stock dividend activity during 2011...

Words: 291 - Pages: 2

Premium Essay

Business Case

...including Vioxx™ for the treatment of osteoarthritis, Fosamax™ for the treatment of osteoporosis and Singulair™ for treating asthma. The Company earned $5.9 billion on 1999 sales1 of $32.7 billion, about a 20% increase from 1998. Exhibits 1 and 2 contain Merck’s Income Statement and Balance Sheet. A handful of Merck’s most popular drugs, Vasotec™, Mevacor™, Prinivil™, and Pepcid™, generated $5.7 billion in worldwide sales. The patents for these drugs, however, would expire by 20022. Once the patents expired, Merck anticipated that the sales of these drugs would decline substantially as generic substitutes became available. The only way to counter the loss of sales from drugs going off patent was to develop new drugs and constantly refresh the company’s portfolio. The company develops new compounds primarily through internal research, but complements this 1 Including $15.2 Billion in Medco (PBM) sales. 2 Deutsche Bank Equity Analyst Report, January 2000. ________________________________________________________________________________________________________________ David Krieger (MBA ‘00) and Professor Richard S. Ruback prepared this case. HBS cases are developed solely as the basis for class discussion. Cases are not intended to serve as endorsements, sources of primary data, or illustrations of effective or ineffective management. Copyright © 2000 President and Fellows of Harvard College. To order copies or request permission to reproduce materials, call......

Words: 2603 - Pages: 11

Premium Essay

Case Study of Merck's Acquisition of Medco

...income. Recommendation: After careful thought and analysis it is my recommendation to the Board of Directors the Merck tender a cash bid of $6.6 Billion to acquire Medco Containment Services Incorporated. Medco has shown that Prescription Benefit Management companies are becoming a vital force within the pharmaceutical industry. Merck must adapt to the changing market place to remain profitable and competitive and the resources available through Medco will drastically change the ability of Merck to generate revenue. Acquiring Medco will give Merck the distribution channel needed to market its prescription drugs. Given the large amount of relationships serviced by Medco, and nearly 33 Million individual clients that rely on them, Merck’s acquisition of Medco will yield vast amount of information about the drug prescribing habits of physicians and purchase and refill habits of consumers. The combined company will be able to market and sell Merck products at reduced costs due in large part to the databases created and maintained by Medco. Overlapping marketing operations will be combined and the overall sales force reduced as targeted marketing strategies are created using the information on hand. Overall synergy should be good as the research and development expertise of Merck will complement the distribution and information gathering abilities of Medco. While company culture and operational differences are of some concern, I believe they have only minimal......

Words: 2193 - Pages: 9

扫一扫安装APKPure 客户端 | Kubikiri Cycle: Aoiro Savant to Zaregototsukai English Subbed | Watch movie